目的 探讨济生肾气丸联合氯沙坦钾片治疗慢性肾小球肾炎的临床疗效。方法 选取2019年1月—2023年2月在安徽医科大学附属宿州医院治疗的88例慢性肾小球肾炎患者，随机分为对照组（44例）和治疗组（44例）。对照组口服氯沙坦钾片，100 mg/次，1次/d。治疗组患者在对照组基础上口服济生肾气丸，1丸/次，3次/d。两组患者均治疗2个月。观察两组患者临床疗效，比较治疗前后两组患者肾功能指标胱抑素C（CysC）、尿中性粒细胞明胶酶相关脂质运载蛋白（NGAL）和尿视黄醇结合蛋白（RBP）水平，及炎症指标白细胞介素-6（IL-6）、γ干扰素（IFN-γ）、肿瘤坏死因子-α（TNF-α）水平。结果 治疗后，治疗组患者总有效率为90.91%，明显高于对照组的75.00%（P＜0.05）。治疗后，两组患者血清CysC、尿NGAL、尿RBP水平及血清IL-6、IFN-γ、TNF-α水平均明显降低（P＜0.05），且治疗组患者降低幅度明显大于对照组（P＜0.05）。结论 济生肾气丸联合氯沙坦钾片治疗慢性肾小球肾炎具有较好的临床疗效，可有效改善患者的肾功能以及炎症反应。

Objective To explore the clinical efficacy of Jisheng Shenqi Pills and losartan potassium in treatment of chronic glomerulonephritis. Methods Patients (88 cases) with chronic glomerulonephritis in Suzhou Hospital of Anhui Medical University from January 2019 to February 2023 were randomly divided into control (44 cases) and treatment (44 cases) group. Patients in the control group were po administered with Losartan Potassium Tablets, 100 mg/time, once daily. Patients in the treatment group were po administered with Jisheng Shenqi Pills on the basis of the control group,1 pill/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical evaluation was evaluated, and the levels of renal function indicators CysC, NGAL and RBP, the levels of inflammatory indicators IL-6, IFN-γ and TNF-α in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 90.91%, which was significantly higher than that of the control group (75.00%, P < 0.05). After treatment, the levels of serum CysC, urinary NGAL, urinary RBP, and serum IL-6, IFN-γ and TNF-α levels in two groups were significantly decreased (P < 0.05), and the decrease in the treatment group was significantly higher than that in the control group (P < 0.05). Conclusion The combination of Jisheng Shenqi Pills and Losartan Potassium Tablets has good clinical efficacy in the treatment of chronic glomerulonephritis, which can effectively improve the renal function and inflammatory response.

R983

安徽省卫生健康委科研项目（2019SEY020）